MetMED
Phase III randomized double-blind placebo-controlled trial of metformin for white matter repair and cognitive recovery in paediatric brain tumour patients
Brain and other Central Nervous System (CNS) Tumours
Survival rates for paediatric brain tumours has risen to between 50% – 70% over the past 25 years. However, treatment for such aggressive cancers is not without side effects. Radiation treatment in particular leaves many children/adolescents suffering from long-term cognitive impairment and brain injuries impacting learning and behavioural issues.
This 16-week study is to trial the use of the drug Metformin, an oral medication already widely used for diabetes. It will investigate if metformin can promote cognitive recovery and brain growth in children/adolescents treated for medulloblastoma.
Disease stage: Post treatment
Patient age range: 7 Years to 17 Years and 11 months
Trial sponsors:
- National: ANZCHOG
- International: Hospital for Sick Kids, Toronto
Sites
John Hunter Children’s Hospital
Monash Children’s Hospital, Melbourne
Perth Children’s Hospital
The Royal Children’s Hospital, Melbourne
